ARIAD to Present Data on Deforolimus and AP24534 at 20th Annual EORTC-NCI-AACR Symposium
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data from clinical and preclinical studies evaluating the company’s investigational small molecule cancer therapies – its mTOR inhibitor deforolimus, and its multi-targeted kinase inhibitor AP24534 – will be presented during the 20th Annual EORTC-NCI-AACR (ENA) Symposium on “Molecular Targets and Cancer Therapeutics,” being held in Geneva, Switzerland from October 21 through October 24, 2008.
The schedule of presentations for ARIAD’s drug candidates is as follows:
Abstract Title: Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK-8669) in phase Ib studies Poster: Catapano, C. (CH) Session: Pharmacogenomics Number: 195 Date/Time: Wednesday, October 22, 2008 / 12:00 pm – 2:15 pm GST Abstract Title: A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules Poster: Berk, L. (US) Session: mTOR Number: 321 Date/Time: Thursday, October 23, 2008 / 12:00 pm – 3:00 pm GST Abstract Title: Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models Poster: Squillace, T. (US) Session: mTOR Number: 324 Date/Time: Thursday, October 23, 2008 / 12:00 pm – 3:00 pm GST Abstract Title: AP24534: an orally active kinase inhibitor that targets multiple pro-angiogenic receptors and exhibits potent anti-tumor activity in vivo Poster: Rivera, V. (US) Session: Signal transduction modulators Number: 553 Date/Time: Friday, October 24, 2008 / 12:00 pm – 4:00 pm GST
In collaboration with Merck & Co., Inc., deforolimus is being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer.
This ENA Symposium is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). It is organized to bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. This conference highlights many recent advances in the early development of promising new compounds at various levels of preclinical and clinical development.
About ARIAD
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need – aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD’s lead cancer product candidate, which is in Phase 3 clinical development. ARIAD’s second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.
This press release contains “forward-looking statements.” Forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on our strategic partners and licensees and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner’s product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our NF-(kappa)B patent portfolio, the merger of the Company with its former subsidiary, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economic conditions, prices, reimbursement rates and competition, and other factors detailed in the Company’s public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company’s expectations, except as required by law.